HM15211 vs Dulaglutide
Head-to-head comparison of HM15211 (HM15211, glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide/glucagon receptor triagonist) and Dulaglutide (Recombinant GLP-1 receptor agonist Fc fusion protein) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | HM15211 | Dulaglutide |
|---|---|---|
| Category | Weight Management | Weight Management |
| Full Name | HM15211, glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide/glucagon receptor triagonist | Recombinant GLP-1 receptor agonist Fc fusion protein |
| Molecular Weight | N/A | ~63,000 Da |
| Half-Life | Approximately 1 week | About 5 days |
| Amino Acids | N/A | N/A |
| Typical Dose | Investigational; no established human dose | 0.75-4.5 mg weekly |
| Route | Subcutaneous | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 12 | 700 |
| Research Status | Clinical | Approved |
HM15211 Benefits
- ✓appetite suppression
- ✓greater fat oxidation
- ✓weight loss
- ✓improved metabolic markers
Dulaglutide Benefits
- ✓modest weight loss
- ✓lower A1c
- ✓weekly dosing convenience
- ✓cardiometabolic benefit
HM15211 Dosing
once-weekly subcutaneous injection|titration to effect|maintenance at tolerated dose
Dulaglutide Dosing
0.75-4.5 mg SC weekly|Increase based on response and tolerance|Administer on the same day each week
HM15211 Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠reduced appetite
Dulaglutide Side Effects
- ⚠nausea
- ⚠diarrhea
- ⚠injection-site reactions
Research Overview
HM15211
Research has shown potent weight-reducing and metabolic effects in preclinical and translational studies. The compound is being developed as a next-generation incretin-based therapy.
Dulaglutide
Dulaglutide has repeatedly shown small-to-moderate reductions in body weight alongside glycemic improvement in large diabetes trials. It is a useful comparator for GLP-1 receptor agonist effects on appetite and weight.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.